Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT.
CNS tumors
Incidence
Prevalence
Rare tumors
Survival
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
12
07
2023
accepted:
11
10
2023
medline:
1
12
2023
pubmed:
19
11
2023
entrez:
19
11
2023
Statut:
ppublish
Résumé
Incidence, prevalence, and survival are population-based statistics describing cancer burden. The National Cancer Institute's (NCI) Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) specializes in tumor biology and outcomes for 12 rare CNS tumor types selected for their importance in adults, research interest, or potential for targeted treatment. The aim of this study was to update incidence, prevalence, and survival statistics for these tumors. The Central Brain Tumor Registry of the United States (CBTRUS) database, a combined dataset of Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR) and NCI's Surveillance, Epidemiology and End Results (SEER) data, was used to calculate average annual age-adjusted incidence rates (AAAIR) per 100,000 population overall and by sex, race-ethnicity, and age for diagnosis years 2008-2019. Incidence time trends were calculated for diagnosis years 2004-2019. NPCR data were used to calculate relative survival rates. Point prevalence on December 31, 2019 was estimated using annual age-specific incidence and survival. AAAIR was 1.47 per 100,000 for these tumors combined, with highest incidence in ependymomas (AAAIR = 0.41/100,000). Most tumor types were more common in males, adults (ages 40 + years) or children (ages < 15 years), and non-Hispanic White individuals. Ependymomas were the most prevalent tumor type (19,320 cases) followed by oligodendrogliomas (14,900 cases). Ependymomas had the highest five-year survival (90.6%) and primary CNS sarcomas the lowest (7.7%). These data provide means to measure the impact of clinical care and evaluate new therapies and the evolving histopathology definitions in rare CNS tumor types.
Identifiants
pubmed: 37980692
doi: 10.1007/s11060-023-04480-7
pii: 10.1007/s11060-023-04480-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
279-290Subventions
Organisme : CDC HHS
ID : Contract No.75D30119C06056/Amendment 0003
Pays : United States
Organisme : NIH HHS
ID : Contract No.75N91022P00827
Pays : United States
Organisme : CDC HHS
ID : Contract No.75D30119C06056/Amendment 0003
Pays : United States
Organisme : CDC HHS
ID : Contract No.75D30119C06056/Amendment 0003
Pays : United States
Organisme : CDC HHS
ID : Contract No.75D30119C06056/Amendment 0003
Pays : United States
Organisme : CDC HHS
ID : Contract No.75D30119C06056/Amendment 0003
Pays : United States
Organisme : NIH HHS
ID : Contract No.75N91022P00827
Pays : United States
Organisme : NIH HHS
ID : Contract No.75N91022P00827
Pays : United States
Organisme : NIH HHS
ID : Contract No.75N91022P00827
Pays : United States
Organisme : NIH HHS
ID : Contract No.75N91022P00827
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2022) CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol 24:v1–v95. https://doi.org/10.1093/neuonc/noac202
doi: 10.1093/neuonc/noac202
pubmed: 36196752
pmcid: 9533228
National Cancer Institute N-C NCI-CONNECT Rare Brain and Spine Tumor Network. https://www.cancer.gov/rare-brain-spine-tumor/
Truitt G, Gittleman H, Leece R, Ostrom QT, Kruchko C, Armstrong TS, Gilbert MR, Barnholtz-Sloan JS (2019) Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. J Neurooncol 144:53–63. https://doi.org/10.1007/s11060-019-03215-x
doi: 10.1007/s11060-019-03215-x
pubmed: 31209773
pmcid: 8127387
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Central Brain Tumor Registry of the United States SEER*Stat Database (2022) CDC National program of cancer registries and NCI surveillance, epidemiology and end results incidence data, 2021 submission (2000–2019)
Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, Ruhl J, Waite KA, Negoita S, Hofferkamp J, Tihan T, McLendon R, Brat DJ, Ostrom QT, Barnholtz-Sloan JS (2022) Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro Oncol 24:1989–2000. https://doi.org/10.1093/neuonc/noac113
doi: 10.1093/neuonc/noac113
pubmed: 35460555
pmcid: 9629432
Kruchko C, Gittleman H, Ruhl J, Hofferkamp J, Ward EM, Ostrom QT, Sherman RL, Jones SF, Barnholtz-Sloan JS, Wilson RJ (2019) Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors. Neurooncol Pract 6:330–339. https://doi.org/10.1093/nop/npz029
doi: 10.1093/nop/npz029
pubmed: 31555447
pmcid: 6753356
Surveillance Epidemiology and End Results (SEER) Program (2022) SEER*Stat software version 8.4.0. National cancer institute, DCCPS, Surveillance research program. www.seer.cancer.gov/seerstat .
Fay MP (1999) Approximate confidence intervals for rate ratios from directly standardized rates with sparse data. Commun Stat Theory Methods 28:2141–2160. https://doi.org/10.1080/03610929908832411
doi: 10.1080/03610929908832411
Fay MP, Tiwari RC, Feuer EJ, Zhaohui Z (2006) Estimating average annual percent change for disease rates without assuming constant change. Biometrics 62:847–854
doi: 10.1111/j.1541-0420.2006.00528.x
pubmed: 16984328
Joinpoint Regression Program, Version 5.0.2.0 (2023) Statistical methodology and applications branch, surveillance research program, national cancer institute. https://surveillance.cancer.gov/joinpoint/
Neff C, Zhang A, Price M, Barnholtz-Sloan J, Ostrom Q (2022) prevEst (version 2.0). https://github.com/ostrom-lab/prevEst
Surveillance Epidemiology and End Results (SEER) Program (2022) SEER*Stat database: incidence - SEER research plus data, 17 Registries, Nov 2021 Sub (2000–2019) linked To county attributes total U.S., 1969–2020 counties, National Cancer Institute, DCCPS, Surveillance research program, released April 2022, based on the November 2021 submission
U.S. Cancer Statistics Working Group (2022) NPCR Survival analytical database, November 2021 Submission, Diagnosis year 2001–2018
Greenfield JP, Castaneda Heredia A, George E, Kieran MW, Morales La Madrid A (2016) Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26–27, 2015, Paris, France. Pediatr Blood Cancer 63:2072–2077. https://doi.org/10.1002/pbc.26169
doi: 10.1002/pbc.26169
pubmed: 27466787
Louis DN OH, Wiestler OD, Cavanee WK (ed) (2016) WHO Classification of tumours of the central nervous system. International agency for research on cancer, Lyon, France
Chan MY, Teo WY, Seow WT, Tan AM (2007) Epidemiology, management and treatment outcome of medulloblastoma in singapore. Ann Acad Med Singapore 36:314–318
doi: 10.47102/annals-acadmedsg.V36N5p314
pubmed: 17549276
Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M (2019) Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol 143:87–93
doi: 10.1007/s11060-019-03134-x
pubmed: 30864101
pmcid: 6482123
Vitanza NA, Partap S (2016) Pediatric ependymoma. J Child Neurol 31:1354–1366. https://doi.org/10.1177/0883073815610428
doi: 10.1177/0883073815610428
pubmed: 26503805
Wu J, Armstrong TS, Gilbert MR (2016) Biology and management of ependymomas. Neuro Oncol 18:902–913. https://doi.org/10.1093/neuonc/now016
doi: 10.1093/neuonc/now016
pubmed: 27022130
pmcid: 4896548
Archer TC, Mahoney EL, Pomeroy SL (2017) Medulloblastoma: molecular classification-based personal therapeutics. Neurotherapeutics 14:265–273. https://doi.org/10.1007/s13311-017-0526-y
doi: 10.1007/s13311-017-0526-y
pubmed: 28386677
pmcid: 5398996
Salloum R, Chen Y, Yasui Y, Packer R, Leisenring W, Wells E, King A, Howell R, Gibson TM, Krull KR, Robison LL, Oeffinger KC, Fouladi M, Armstrong GT (2019) Late morbidity and mortality among medulloblastoma survivors diagnosed across three decades: a report from the childhood cancer survivor study. J Clin Oncol 37:731–740
doi: 10.1200/JCO.18.00969
pubmed: 30730781
pmcid: 6424138
Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, Ruhl J, Waite K, Negoita S, Hofferkamp J, Tihan T, McLendon R, Brat DJ, Ostrom QT, Barnholtz-Sloan JS (2022) Molecular biomarker-defined brain tumors: epidemiology, validity, and completeness in the United States. Neuro Oncol. https://doi.org/10.1093/neuonc/noac113
doi: 10.1093/neuonc/noac113
pubmed: 35460555
pmcid: 10076944
Shepard MJ, Haider AS, Prabhu SS, Sawaya R, DeMonte F, McCutcheon IE, Weinberg JS, Ferguson SD, Suki D, Fuller GN, Lang FF (2022) Long term outcomes following surgery for pineal region tumors. J Neurooncol 156:491–498. https://doi.org/10.1007/s11060-021-03919-z
doi: 10.1007/s11060-021-03919-z
pubmed: 35083579
Gonzalez Castro LN, Wesseling P (2020) The cIMPACT-NOW updates and their significance to current neuro-oncology practice. Neurooncol Pract 8:4–10. https://doi.org/10.1093/nop/npaa055
doi: 10.1093/nop/npaa055
pubmed: 33664964
pmcid: 7906262
Pinheiro PS, Morris CR, Liu L, Bungum TJ, Altekruse SF (2014) The impact of follow-up type and missed deaths on population-based cancer survival studies for hispanics and asians. JNCI Monographs 2014:210–217. https://doi.org/10.1093/jncimonographs/lgu016
doi: 10.1093/jncimonographs/lgu016